PubRank

P Mauch

Author PubWeight™ 81.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. Int J Radiat Oncol Biol Phys 1996 2.44
2 Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995 1.66
3 High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998 1.61
4 Quantitation of murine hematopoietic stem cells in vitro by limiting dilution analysis of cobblestone area formation on a clonal stromal cell line. Exp Hematol 1993 1.51
5 Evidence for structured variation in self-renewal capacity within long-term bone marrow cultures. Proc Natl Acad Sci U S A 1980 1.38
6 Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992 1.23
7 Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999 1.21
8 Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993 1.14
9 Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994 1.11
10 Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996 1.10
11 T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001 1.07
12 The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978 1.05
13 CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997 1.04
14 The effect of donor T lymphocytes and total-body irradiation on hemopoietic engraftment and pulmonary toxicity following experimental allogeneic bone marrow transplantation. Transplantation 1992 1.03
15 B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996 1.01
16 The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985 1.01
17 Decline in bone marrow proliferative capacity as a function of age. Blood 1982 0.98
18 Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 1992 0.97
19 Engraftment following T cell-depleted bone marrow transplantation. III. Differential effects of increased total-body irradiation on semiallogeneic and allogeneic recipients. Transplantation 1988 0.96
20 Radiographic features of recurrent intrathoracic Hodgkin's disease following radiation therapy. AJR Am J Roentgenol 1979 0.95
21 Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1988 0.94
22 Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 1985 0.94
23 Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995 0.93
24 Biochemical genetics of TL antigens. Immunogenetics 1986 0.93
25 Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993 0.93
26 Renal insufficiency after total body irradiation for pediatric bone marrow transplantation. Radiother Oncol 1990 0.91
27 Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol 1985 0.91
28 Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet 1993 0.91
29 Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993 0.91
30 Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol 1993 0.90
31 Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003 0.90
32 High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996 0.89
33 Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 2004 0.89
34 Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 1982 0.88
35 Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999 0.88
36 Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993 0.88
37 Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002 0.87
38 Thoracic irradiation in Hodgkin's disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 1990 0.87
39 The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002 0.87
40 Lung metastases in cervical and endometrial carcinoma. AJR Am J Roentgenol 1979 0.87
41 Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999 0.87
42 CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001 0.86
43 Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994 0.86
44 Engraftment following T-cell-depleted marrow transplantation. I. The role of major and minor histocompatibility barriers. Transplantation 1987 0.86
45 Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998 0.85
46 Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990 0.85
47 Anatomic substages of stage III-A Hodgkin's disease. A collaborative study. Ann Intern Med 1980 0.85
48 High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997 0.85
49 Synergistic effects of interleukin-11 with other growth factors on the expansion of murine hematopoietic progenitors and maintenance of stem cells in liquid culture. Exp Hematol 1994 0.85
50 Fractionation and dose rate effects in mice: a model for bone marrow transplantation in man. Int J Radiat Oncol Biol Phys 1987 0.85
51 The place of radiation therapy in the treatment of Hodgkin's disease. Cancer 1978 0.84
52 Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987 0.84
53 Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. Cancer Treat Rep 1982 0.84
54 Dose-limiting complications from upper half body irradiation in C3H mice. Int J Radiat Oncol Biol Phys 1988 0.82
55 The development of Graves' disease following radiation therapy in Hodgkin's disease. Int J Radiat Oncol Biol Phys 1988 0.82
56 Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 1995 0.81
57 Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 2001 0.81
58 The significance of positive chorionic gonadotropins in apparently pure seminoma of the testis. Int J Radiat Oncol Biol Phys 1979 0.81
59 T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood 1990 0.81
60 CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 1998 0.81
61 Peri- and paracardial involvement in lymphoma: a radiographic study of 11 cases. AJR Am J Roentgenol 1983 0.80
62 Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991 0.80
63 Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993 0.80
64 Stages IIB and IIIB Hodgkin's disease. Results of combined modality treatment. Cancer 1977 0.80
65 Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003 0.80
66 Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991 0.80
67 Functional organization of the hematopoietic stem cell compartment: implications for cancer and its therapy. J Clin Oncol 1983 0.80
68 Lethal graft-versus-host disease: modification with allogeneic cultured donor cells. Blood 1984 0.79
69 Cell types associated with fibronectin in long-term mouse bone marrow cultures. J Histochem Cytochem 1982 0.79
70 Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 1997 0.79
71 Evidence that anti-LFA-1 in vivo improves engraftment and survival after allogeneic bone marrow transplantation. Transplantation 1990 0.78
72 Circulating lymphocyte populations in Hodgkin's disease after mantle and paraaortic irradiation. Blood 1983 0.78
73 Engraftment following T-cell-depleted bone marrow transplantation. II. Stability of mixed chimerism in semiallogeneic recipients after total-body irradiation. Transplantation 1987 0.78
74 Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991 0.78
75 Role of radiation therapy in the treatment of Hodgkin's disease. Cancer Treat Rep 1982 0.77
76 CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant 1997 0.77
77 Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. Ann Oncol 2004 0.77
78 Radiotherapy versus combined modality in early stages. Ann Oncol 1992 0.77
79 Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol 1989 0.77
80 Reduction of marrow hematopoietic progenitor and stem cell content is not sufficient for enhanced syngeneic engraftment. Stem Cells 2000 0.77
81 Second malignancies after curative radiation therapy for good prognosis cancers. Int J Radiat Oncol Biol Phys 1995 0.77
82 Late complications following total-body irradiation and bone marrow rescue in mice: predominance of glomerular nephropathy and hemolytic anemia. Int J Radiat Biol 1990 0.76
83 Evidence that anti-asialo GM1 in vivo improves engraftment of T cell-depleted bone marrow in hybrid recipients. Transplantation 1990 0.76
84 Anatomic substages of stage IIIA Hodgkin's disease: followup of a collaborative study. Cancer Treat Rep 1982 0.76
85 Reduction of lethal graft-versus-host disease: transplantation of cultured murine bone marrow across minor histocompatibility differences. Blood 1985 0.76
86 Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. AJR Am J Roentgenol 1996 0.76
87 Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol 1985 0.76
88 Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma 1995 0.75
89 Reduction of treatment for early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1992 0.75
90 What is the role for adjuvant radiation therapy in advanced Hodgkin's disease? J Clin Oncol 1998 0.75
91 [Tamponade using silastic sponge in comminution fractures of the maxillary sinus and orbital floor]. Z Laryngol Rhinol Otol 1970 0.75
92 Response to "Dilemmas and decisions". Int J Radiat Oncol Biol Phys 1990 0.75
93 Prognostic factors in patients with subdiaphragmatic Hodgkin's disease. Hematol Oncol 1984 0.75
94 An evaluation of total nodal irradiation as treatment for stage III A Hodgkin's disease. Cancer 1979 0.75
95 [Treatment of early stage Hodgkin disease]. Ugeskr Laeger 1993 0.75
96 Implications of a proliferative limitation on hematopoietic stem cells. Prog Clin Biol Res 1984 0.75
97 Treatment of patients with "minimal" stage IIIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 1987 0.75
98 The Second International Symposium on Hodgkin's Disease. Workshop I: Review on prognostic factors. Ann Oncol 1992 0.75
99 Bone marrow transplantation: the genetic and cellular basis of resistance to engraftment and acute graft-versus-host disease. Surv Immunol Res 1985 0.75
100 Mediastinal Hodgkin's disease. Significance of mediastinal involvement in early stage Hodgkin's disease. Hematol Oncol 1984 0.75
101 Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer 1993 0.75
102 Mdr1 gene-expression in a multidrug-resistant human non-hodgkins-lymphoma xenograft model. Int J Oncol 1993 0.75
103 Mutagenesis after therapy for Hodgkin's disease. Hematol Oncol Clin North Am 1993 0.75
104 The role of MOPP chemotherapy in early stage Hodgkin's disease. Hematol Oncol 1984 0.75
105 The influence of initial pathologic stage on the survival of patients who relapse from Hodgkin's disease. Blood 1980 0.75
106 Removal of carcinoma cells from contaminated bone marrow using the lipophilic cation rhodamine 123. Clin Cancer Res 1995 0.75
107 The IgM and IgA immune response to the TNP determinant group in BALB-c mice. J Immunol 1974 0.75
108 Supradiaphragmatic Hodgkin's disease: is there a role for MOPP chemotherapy in patients with bulky mediastinal disease? Int J Radiat Oncol Biol Phys 1980 0.75
109 Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy. J Clin Oncol 1987 0.75
110 The role of postoperative local or regional irradiation in the treatment of stage I ovarian cancer. Radiology 1982 0.75
111 Three-dimensional dose distribution of total body irradiation by a dual source total body irradiator. Int J Radiat Oncol Biol Phys 1992 0.75
112 A prospective study of hprt mutant and mutation frequencies in treated cancer patients. Cancer Epidemiol Biomarkers Prev 1993 0.75
113 Autologous bone marrow transplantation for patients with advanced lymphomas: improvement of a promising investigational technique. Cancer Invest 1988 0.75
114 Pediatric stage IV Hodgkin disease. Long-term survival. Cancer 1993 0.75